发布求助
文献互助 智能选刊 最新文献

Bone Marrow Research最新文献

筛选
英文 中文
An in vitro study of differentiation of hematopoietic cells to endothelial cells. 造血细胞向内皮细胞分化的体外研究。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-12-29 DOI: 10.1155/2011/846096
Qi Ru Wang, Bao He Wang, Wen Biao Zhu, Yan Hong Huang, Yi Li, Qi Yan
{"title":"An in vitro study of differentiation of hematopoietic cells to endothelial cells.","authors":"Qi Ru Wang,&nbsp;Bao He Wang,&nbsp;Wen Biao Zhu,&nbsp;Yan Hong Huang,&nbsp;Yi Li,&nbsp;Qi Yan","doi":"10.1155/2011/846096","DOIUrl":"https://doi.org/10.1155/2011/846096","url":null,"abstract":"<p><p>Bone-marrow-derived endothelial progenitor cells (BM-EPCs) contribute to postnatal neovascularization and therefore are of great interest for cell therapies to treat ischemic diseases. However, their origin and characteristics are still in controversy. In this paper, we identified the origin/lineage of the BM-EPCs that were isolated from bone marrow mononuclear cells and differentiated with the induction of bone-marrow endothelial-cellconditioned medium (ECCM). BM-EPCs were characterized in terms of phenotype, lineage potential, and their functional properties. Endothelial cell colonies derived from BM-EPC were cultured with ECCM for 3 months. Cultured EPC colony cells expressed endothelial cell markers and formed the capillary-like network in vitro. EPC colony cells expressed differential proliferative capacity; some of the colonies exhibited a high proliferative potential (HPP) capacity up to 20 population doublings. More importantly, these HPP-EPCs expressed hematopoietic marker CD45, exhibited endocytic activities, and preserved some of the myeloid cell activity. In addition, the HPP-EPCs secrete various growth factors including VEGF and GM-CSF into the culture medium. The results demonstrate that these EPCs were primarily derived from hematopoietic origin of early precursor cells and maintained high proliferative potential capacity, a feature with a significant potential in the application of cell therapy in ischemic diseases.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/846096","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30384158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney). 铸型肾病(肾骨髓瘤)的发病机制和治疗的最新进展。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-05-04 DOI: 10.1155/2011/493697
Stephanie Stringer, Kolitha Basnayake, Colin Hutchison, Paul Cockwell
{"title":"Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).","authors":"Stephanie Stringer,&nbsp;Kolitha Basnayake,&nbsp;Colin Hutchison,&nbsp;Paul Cockwell","doi":"10.1155/2011/493697","DOIUrl":"https://doi.org/10.1155/2011/493697","url":null,"abstract":"<p><p>Multiple myeloma is an incurable plasma cell malignancy that is often accompanied by renal failure; there are a number of potential causes of this, of which cast nephropathy is the most important. Renal failure is highly significant in myeloma, as patient survival can be stratified by the severity of the renal impairment. Consequently, there is an ongoing focus on the pathological basis of cast nephropathy and the optimal treatment regimens in this setting, including effective chemotherapy regimens to reduce light chain production and emerging extracorporeal techniques to remove circulating light chains. This paper bridges recent advances in the pathogenesis and management of cast nephropathy in multiple myeloma.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/493697","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40122337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. 骨髓干细胞衍生的旁分泌因子用于再生医学:目前的观点和治疗潜力。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2010-12-06 DOI: 10.1155/2011/207326
Tom J Burdon, Arghya Paul, Nicolas Noiseux, Satya Prakash, Dominique Shum-Tim
{"title":"Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential.","authors":"Tom J Burdon,&nbsp;Arghya Paul,&nbsp;Nicolas Noiseux,&nbsp;Satya Prakash,&nbsp;Dominique Shum-Tim","doi":"10.1155/2011/207326","DOIUrl":"https://doi.org/10.1155/2011/207326","url":null,"abstract":"<p><p>During the past several years, there has been intense research in the field of bone marrow-derived stem cell (BMSC) therapy to facilitate its translation into clinical setting. Although a lot has been accomplished, plenty of challenges lie ahead. Furthermore, there is a growing body of evidence showing that administration of BMSC-derived conditioned media (BMSC-CM) can recapitulate the beneficial effects observed after stem cell therapy. BMSCs produce a wide range of cytokines and chemokines that have, until now, shown extensive therapeutic potential. These paracrine mechanisms could be as diverse as stimulating receptor-mediated survival pathways, inducing stem cell homing and differentiation or regulating the anti-inflammatory effects in wounded areas. The current review reflects the rapid shift of interest from BMSC to BMSC-CM to alleviate many logistical and technical issues regarding cell therapy and evaluates its future potential as an effective regenerative therapy.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/207326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40122886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 137
Hyperbaric oxygen therapy as a sole agent is not immunosuppressant in a highly immunogenic mouse model. 在高度免疫原性小鼠模型中，高压氧治疗作为单一药物不具有免疫抑制作用。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2010-08-03 DOI: 10.1155/2011/579268
Adam Gassas, Weixian Min, A Wayne Evans, Susan Carter, George K Sándor, Eyal Grunebaum
{"title":"Hyperbaric oxygen therapy as a sole agent is not immunosuppressant in a highly immunogenic mouse model.","authors":"Adam Gassas,&nbsp;Weixian Min,&nbsp;A Wayne Evans,&nbsp;Susan Carter,&nbsp;George K Sándor,&nbsp;Eyal Grunebaum","doi":"10.1155/2011/579268","DOIUrl":"https://doi.org/10.1155/2011/579268","url":null,"abstract":"<p><p>Background. Hyperbaric oxygen (HBO) therapy, which is used for many conditions, may also have immunosuppressive effects and could be used for prevention or treatment of graft-versus-host disease (GvHD). If HBO is immunosuppressant, then we hypothesize that HBO therapy will delay the T-cell mediated skin graft rejection. Methods. C57/BL6 black-coated (H2B) mice received skin graft from CBA (H2D) white-coated mice. Mice were treated with either 19 session of 240 kpa oxygen or 29 session of 300 kpa oxygen, for 90 minutes. Mice were housed either 4 per cage or separately, to prevent friction and mechanical factors that may affect graft survival. Skin grafts were assessed daily. Results. There was no difference in length of graft survival between mice that received either regimens of HBO therapy and mice that did not receive HBO therapy. Conclusions. HBO therapy, as a sole agent, did not delay skin graft rejection in a highly immunogenic mouse model.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/579268","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40121233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Multiple myeloma: a review of imaging features and radiological techniques. 多发性骨髓瘤:影像学特征和放射学技术综述。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-08-08 DOI: 10.1155/2011/583439
C F Healy, J G Murray, S J Eustace, J Madewell, P J O'Gorman, P O'Sullivan
{"title":"Multiple myeloma: a review of imaging features and radiological techniques.","authors":"C F Healy,&nbsp;J G Murray,&nbsp;S J Eustace,&nbsp;J Madewell,&nbsp;P J O'Gorman,&nbsp;P O'Sullivan","doi":"10.1155/2011/583439","DOIUrl":"https://doi.org/10.1155/2011/583439","url":null,"abstract":"<p><p>The recently updated Durie/Salmon PLUS staging system published in 2006 highlights the many advances that have been made in the imaging of multiple myeloma, a common malignancy of plasma cells. In this article, we shall focus primarily on the more sensitive and specific whole-body imaging techniques, including whole-body computed tomography, whole-body magnetic resonance imaging, and positron emission computed tomography. We shall also discuss new and emerging imaging techniques and future developments in the radiological assessment of multiple myeloma.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/583439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40121234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 84
Antibody-based therapies in multiple myeloma. 多发性骨髓瘤的抗体疗法。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-03-02 DOI: 10.1155/2011/924058
Yu-Tzu Tai, Kenneth C Anderson
{"title":"Antibody-based therapies in multiple myeloma.","authors":"Yu-Tzu Tai, Kenneth C Anderson","doi":"10.1155/2011/924058","DOIUrl":"10.1155/2011/924058","url":null,"abstract":"<p><p>The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies (mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors, therapeutic mAbs present the potential to specifically target tumor cells and directly induce an immune response to lyse tumor cells. Unique immune-effector mechanisms are only triggered by therapeutic mAbs but not by small molecule targeting agents. Although therapeutic murine mAbs or chimeric mAbs can cause immunogenicity, the advancement of genetic recombination for humanizing rodent mAbs has allowed large-scale production and designation of mAbs with better affinities, efficient selection, decreasing immunogenicity, and improved effector functions. These advancements of antibody engineering technologies have largely overcome the critical obstacle of antibody immunogenicity and enabled the development and subsequent Food and Drug Administration (FDA) approval of therapeutic Abs for cancer and other diseases.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3200112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40121238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors influencing the abundance of the side population in a human myeloma cell line. 影响人类骨髓瘤细胞系侧群丰度的因素。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-09-22 DOI: 10.1155/2011/524845
Sui-Lin Mo, Jia Li, Yen S Loh, Ross D Brown, Adrian L Smith, Yuling Chen, Douglas Joshua, Basil D Roufogalis, George Q Li, Kei Fan, Michelle C H Ng, Daniel Man-Yuen Sze
{"title":"Factors influencing the abundance of the side population in a human myeloma cell line.","authors":"Sui-Lin Mo,&nbsp;Jia Li,&nbsp;Yen S Loh,&nbsp;Ross D Brown,&nbsp;Adrian L Smith,&nbsp;Yuling Chen,&nbsp;Douglas Joshua,&nbsp;Basil D Roufogalis,&nbsp;George Q Li,&nbsp;Kei Fan,&nbsp;Michelle C H Ng,&nbsp;Daniel Man-Yuen Sze","doi":"10.1155/2011/524845","DOIUrl":"https://doi.org/10.1155/2011/524845","url":null,"abstract":"<p><p>Side population (SP) refers to a group of cells, which is capable to efflux Hoechst 33342, a DNA-binding dye. SP cells exist both in normal and tumor tissues. Although SP abundance has been used as an indicator for disease prognostic and drug screening in many research projects, few studies have systematically examined the factors influencing SP analysis. In this study we aim to develop a more thorough understanding of the multiple factors involved in SP analysis including Hoechst 33342 staining and cell culture. RPMI-8226, a high SP percentage (SP%) human myeloma cell line was employed here. The results showed that SP% was subject to staining conditions including: viable cell proportion, dye concentration, staining cell density, incubation duration, staining volume, and mix interval. In addition, SP% was highest in day one after passage, while dropped steadily over time. This study shows that both staining conditions and culture duration can significantly affect SP%. In this case, any conclusions based on SP% should be interpreted cautiously. The relation between culture duration and SP% suggests that the incidence of SP cells may be related to cell proliferation and cell cycle phase. Maintaining these technical variables consistently is essential in SP research.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/524845","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40121231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 33
Oncolytic virotherapy for multiple myeloma: past, present, and future. 多发性骨髓瘤的溶瘤病毒治疗:过去、现在和未来。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-05-10 DOI: 10.1155/2011/632948
Chandini M Thirukkumaran, Don G Morris
{"title":"Oncolytic virotherapy for multiple myeloma: past, present, and future.","authors":"Chandini M Thirukkumaran,&nbsp;Don G Morris","doi":"10.1155/2011/632948","DOIUrl":"https://doi.org/10.1155/2011/632948","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a B-cell malignancy that is currently felt to be incurable. Despite recently approved novel targeted treatments such as lenalidomide and bortezomib, most MM patients' relapse is emphasizing the need for effective and well-tolerated therapies for this deadly disease. The use of oncolytic viruses has garnered significant interest as cancer therapeutics in recent years, and are currently under intense clinical investigation. Both naturally occurring and engineered DNA and RNA viruses have been investigated preclinically as treatment modalities for several solid and hematological malignancies. Presently, only a genetically modified measles virus is in human clinical trials for MM. The information obtained from this and other future clinical trials will guide clinical application of oncolytic viruses as anticancer agents for MM. This paper provides a timely overview of the history of oncolytic viruses for the treatment of MM and future strategies for the optimization of viral therapy for this disease.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/632948","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40121235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. 造血干细胞生态位中间充质干细胞旁分泌分子的研究。
Bone Marrow Research Pub Date : 2011-01-01 Epub Date: 2011-09-22 DOI: 10.1155/2011/353878
Tian Li, Yaojiong Wu
{"title":"Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche.","authors":"Tian Li,&nbsp;Yaojiong Wu","doi":"10.1155/2011/353878","DOIUrl":"https://doi.org/10.1155/2011/353878","url":null,"abstract":"<p><p>Hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are both adult stem cells residing in the bone marrow. MSCs interact with HSCs, they stimulate and enhance the proliferation of HSCs by secreting regulatory molecules and cytokines, providing a specialized microenvironment for controlling the process of hematopoiesis. In this paper we discuss how MSCs contribute to HSC niche, maintain the stemness and proliferation of HSCs, and support HSC transplantation.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2011/353878","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40122334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 71
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信